iShares Health Innovation Active ETF holds a quantitatively derived Bronze Morningstar Medalist Rating. The rating reflects that it has scored better than the norm on factors Morningstar research associates with future outperformance relative to category peers.
iShares Health Innovation Active ETF BMED
Morningstar’s Analysis BMED
Will BMED outperform in the future?
Get our overall rating based on a fundamental assessment of the pillars below.
People Pillar
The People Pillar is our evaluation of the BMED management team’s experience and ability. We find that high-quality management teams deliver superior performance relative to their benchmarks and/or peers.
Parent Pillar
The Parent Pillar is our rating of BMED’s parent organization’s priorities and whether they’re in line with investors’ interests.
- Current Portfolio Date
- Equity Holdings —
- Bond Holdings —
- Other Holdings —
- % Assets in Top 10 Holdings 42.4
|
Top 10 Holdings
|
% Portfolio Weight
|
Market Value USD
|
Sector
|
|---|---|---|---|
BlackRock Cash Funds Treasury SL Agency | 6.23 | 640,000 | Cash and Equivalents |
Merck & Co Inc | 5.83 | 598,565 | Healthcare |
Johnson & Johnson | 5.23 | 536,899 | Healthcare |
Gilead Sciences Inc | 5.06 | 519,667 | Healthcare |
Edwards Lifesciences Corp | 4.74 | 487,340 | Healthcare |
Biogen Inc | 3.77 | 387,097 | Healthcare |
Thermo Fisher Scientific Inc | 3.71 | 380,722 | Healthcare |
Danaher Corp | 3.64 | 374,068 | Healthcare |
Amgen Inc | 3.62 | 371,539 | Healthcare |
Waters Corp | 3.58 | 367,974 | Healthcare |
United States